Investment Rating - The investment rating for the company is "Buy" with an expectation of over 10% return relative to the CSI 300 index in the next six months [11]. Core Views - The company is positioned as a leader in the life care sector, focusing on mosquito repellent and baby care products, with a diversified product line enhancing market competitiveness [5]. - The company achieved a revenue of 1.318 billion yuan in 2024, representing a year-on-year growth of 27.61%, and a net profit of 300 million yuan, up 32.80% year-on-year [5][7]. - The online sales channel has shown significant growth, particularly on platforms like Douyin, contributing to the overall revenue increase [5][7]. - The company is expected to maintain steady growth due to product innovation and channel optimization, with projected net profits of 372 million yuan, 481 million yuan, and 615 million yuan for 2025, 2026, and 2027 respectively [7][9]. Summary by Sections Company Overview - Founded in 2006, the company aims to become a global leader in life and personal care products, offering a range of items including mosquito repellent and baby care products [5]. - The company has established a broad sales network both domestically and internationally, with a strong online presence [5]. Financial Performance - In 2024, the company reported a revenue of 1.318 billion yuan, a 27.61% increase from the previous year, and a net profit of 300 million yuan, reflecting a 32.80% growth [5][9]. - The quarterly revenue breakdown for 2024 shows significant growth, particularly in Q2 and Q4, with Q4 net profit experiencing some fluctuations due to increased promotional expenses [5][7]. Product Performance - The mosquito repellent product line generated 439 million yuan in revenue in 2024, a 35.39% increase, with a gross margin improvement to 54.18% [7]. - The baby care product line achieved 690 million yuan in revenue, up 32.42%, with a gross margin of 59.81% [7]. Channel Strategy - The online sales channel contributed 970 million yuan in revenue, a 23.80% increase, while non-platform distribution revenue reached 347 million yuan, growing by 39.64% [7]. - The company is enhancing its collaboration with e-commerce platforms to optimize its market presence and improve gross margins [7]. Future Projections - The company forecasts continued revenue growth, with expected revenues of 1.710 billion yuan, 2.131 billion yuan, and 2.530 billion yuan for 2025, 2026, and 2027 respectively [9]. - The projected net profit for the next three years indicates a robust growth trajectory, with EPS expected to rise from 0.92 yuan in 2025 to 1.52 yuan in 2027 [9].

润本股份（603193.SH）2024 年年报&2025 年一季报点评 ➢ 风险提示：行业竞争加剧、人口出生率下降风险。 ➢ 线上渠道增长亮眼，婴童护理品类高增驱动业绩增长。分渠道来看： 1）线 上直销，实现营收 7.74 亿元，同比+24.84%；毛利率 63.07%，同比+1.24pct； 2）线上平台经销，实现营收 1.65 亿元，同比+23.38%；毛利率 55.66%，同比 +7.01pct；3）线上平台代销，实现营收 0.31 亿元，同比+4.06%；毛利率 52.09%， 同比+4.45pct；4）非平台经销商，实现营收 3.47 亿元，同比+39.64%；毛利 率 48.89%，同比+1.15pct。分产品来看：1）驱蚊系列，实现营收 4.39 亿元， 同比+35.39%；毛利率实现 54.18%，同比+3.87pct；2）婴童护理系列，实现 营收 6.90 亿元，同比+32.42%；毛利率实现 59.81%，同比+1.52pct；3）精油 系列，实现营收 1.58 亿元，同比+7.88%；毛利率实现 63.44%，同比+0.73pct； 4）其他产品，实现营收 0.30 亿元，同比-25.5 ...

润本生物技术股份有限公司 首次公开发行股票并在主板上市 招股意向书附录 目录 | 序号 | 文件名 | 页码 | | --- | --- | --- | | 1 | 发行保荐书 | 1 | | 2 | 财务报表及审计报告 | 28 | | 3 | 审阅报告 | 173 | | 4 | 内部控制鉴证报告 | 276 | | 5 | 经注册会计师核验的非经常性损益明细表 | 295 | | 6 | 法律意见书 | 306 | | 7 | 律师工作报告 | 495 | | 8 | 公司章程（草案） | 657 | | 9 | 中国证监会同意发行人本次公开发行注册的文件 | 722 | 申万宏源证券承销保荐有限责任公司 关于润本生物技术股份有限公司 首次公开发行股票并在主板上市之 发行保荐书 保荐机构 二〇二三年六月 1 | 目录 2 | | --- | | 第一节 本次证券发行基本情况 4 | | 一、本次具体负责推荐的保荐代表人 4 | | 二、本次证券发行项目协办人及其他项目组成员 4 | | 三、发行人情况 5 | | 四、保荐机构及其关联方与发行人及其关联方之间的利害关系及主要业务往来 | | 情况说明 5 ...